Table 3

Relationship between each of the biomarkers (C1M, C5M, C6M and VICM) and 2-year mSASSS change (unadjusted and adjusted models)

C1MC5MC6MVICM
β (95% CI)β (95% CI)β (95% CI)β (95% CI)
Unadjusted0.01 (0.00 to 0.03)−0.00 (-0.12 to 0.11)−0.00 (-0.03 to 0.02)−0.00 (-0.03 to 0.02)
Adjusted for age, gender and symptom duration0.02 (-0.00 to 0.04)−0.02 (-0.15 to 0.10)−0.00 (-0.03 to 0.03)−0.00 (-0.03 to 0.03)
Adjusted for age, gender, symptom duration and baseline mSASSS0.02 (-0.00 to 0.03)−0.01 (-0.14 to 0.11)−0.00 (-0.03 to 0.03)0.00 (-0.03 to  0.03)
Adjusted for age, gender, symptom duration, mSASSS and CRP0.00 (-0.03 to 0.03)−0.00 (-0.12 to 0.12)−0.01 (-0.04 to 0.02)−0.03 (-0.06 to 0.00)
Adjusted for age, gender, symptom duration, mSASSS and ASDAS0.02 (-0.01 to 0.04)−0.01 (-0.14 to 0.11)−0.00 (-0.03 to 0.02)−0.00 (-0.03 to 0.03)
  • ASDAS, Ankylosing Spondylitis Disease Activity Index; C1M, C5M and C6M, MMP-mediated degradation of type I, V and VI collagen; respectively; CRP, C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine; MMP, matrix metalloproteinase; VICM, citrullinated and MMP-degraded vimentin.